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This paper reports the characterization of the antidiabetic role of a hydroethanolic extract from Parkinsonia aerial parts (HEPA),
in normal and alloxan-induced diabetic rats, treated with HEPA (125 and 250mg/kg; p.o.). Oral glucose tolerance test, acute oral
toxicity test and preliminary phytochemical analyses were performed. The diabetic rats treated with HEPA showed a signiﬁcant
reductioninserumandurinaryglucose,urinaryureaandtriglyceridelevels,ascomparedtothediabeticuntreatedgroup.However,
in the normal treated groups, a signiﬁcant reduction was found only in serum triglyceride levels. In all treated diabetic groups, an
improvement in hepatic glycogen was observed, as well as a decrease in liquid intake and urinary volume, and an enhancement
in the weight of skeletal muscles (soleus and extensor digitorum longus), kidneys and epididymal adipose tissue. Nevertheless, body
andliverweightswereamelioratedonlyinthediabeticgrouptreatedwithHEPA(250mg/kg).Moreover,oralglucosetolerancewas
higher in animals treated with HEPA, while results also showed that HEPA could be considered toxicologically safe. Phytochemical
analysisrevealedthepresenceoftanins,ﬂavonoidsandsteroidsinHEPA.Inconclusion,P.aculeatapresentsanantidiabeticactivity
and other beneﬁcial eﬀects that ameliorate diabetes and associated complications.
1.Introduction
The World Health Organization (WHO) estimates that more
than 180 million people worldwide have diabetes and that
this number is projected to double by year 2030 when this
disorder will be aﬀecting people, irrespective of sex, age, and
socioeconomic status [1, 2]. Currently, conventional drugs
used for diabetes treatment are associated with drawbacks
such as rigid dosing regimens, highcost, inaccessibility, and
unexpected side eﬀects [3, 4]. Therefore, screening for new
antidiabetic compounds from natural plants used in folk
medicine is still attractive because of their eﬃcacy, low
incidence of side eﬀects, and low cost [5, 6]. Ethnobotanical
reports indicate that over 1200 species of plants have been
reported as traditional medicines for diabetes [7]. In Brazil,
medicinal plants are used according to native folk traditions,
or according to the traditions of worldwide immigrants that
use these plants for formulation of home remedies such as
teas, decoctions or tinctures. Around 60% of the population
make use of these kinds of agents because of limited access to
health services and lack of ﬁnancial resources [8]. However,
in order to explore the eﬃcacy, mechanism of action,
and safety of natural products, there is need to perform
preclinical and clinical experiments. WHO suggests the
evaluation of potential eﬀective therapeutic plants, especially
in areaswheresafeandmodern drugsare not available [4,9].
Parkinsonia aculeata L. (Caesalpineaceae) is a medium-
sized tree (4–6m) found in the Xing´ o region (semiarid area)
in the Northeast of Brazil, used as traditional medicine by
the local population and traditional healers for the empiric
treatment of hyperglycemia, without scientiﬁc background
[10]. In addition to these properties, P. aculeata has a wide
range of pharmacological and biological activities, including
antimalarial and antimicrobial properties [11, 12].
A previous study performed by our group demonstrated
theantihyperglycemicandantihyperlipidemicactivitiesofan
aqueous extract fraction of P. aculeata aerial parts in alloxan-
induced diabetic rats [13]. However, studies of this plant are2 Evidence-Based Complementary and Alternative Medicine
rarely reported in the literature. Since, the aqueous extract
fraction of P. aculeata was found to have a high antidia-
betic potential, the study of its hydroethanolic extract was
therefore undertaken to further investigate its antidiabetic
actions in alloxan-induced diabetic as well as in normal rats.
Antidiabetic eﬀects were evaluated by measuring a spectrum
of diabetes-related parameters, such as oral glucose tolerance
and physiological and biochemical parameters related to
carbohydrate, lipid, and protein metabolism. Additionally,
tests for acute oral toxicity and preliminary phytochemical
analyses were also carried out.
2. Methods
2.1. Plant Material. Aerial parts of P. aculeata were collected
from the Xing´ o region (Sergipe, Brazil), during May 2007.
The plant was identiﬁed by Professor H. P. Bautista (INCRA-
BA) and a voucher specimen was deposited (n◦ 500) in
the Xing´ o Herbarium (Canind´ ed oS ˜ ao Francisco, Sergipe,
Northeast region, Brazil).
2.2. Preparation of Plant Extract. Dehydrated and powdered
P. aculeata aerial parts (50g) were macerated with EtOH:
H2O (1:1; v/v). The suspension was submitted to mechanic
agitation for one hour at 23
◦C and subsequently placed
in a refrigerator for 24h and then ﬁltered through cotton
wool. After ﬁltration, the material was lyophilized and stored
at −20
◦C until use. The ﬁnal yield of the hydroethanolic
extract of P. aculeata aerial parts (HEPA) was 7g/50g of the
dried powdered aerial parts. For pharmacological assays, a
freshdilution oflyophilized hydroethanolic extractin vehicle
(distilled water) was prepared on the day of treatment and
administered by gavage at doses of 125 and 250mg/kgb.w. in
aﬁ x e dv o l u m eo f1m L .
2.3. Preliminary Phytochemical Screening. A simple qualita-
tive and semiquantitative phytochemical analysis was carried
out on HEPA for the identiﬁcation of various major classes
of active chemical constituents: alkaloids, saponins, tanins,
ﬂavonoids, and steroids, as described previously in [14, 15].
2.4. Animals. T h es t u d yw a sc a r r i e do u tw i t ha d u l tm a l e
Wistar rats weighing 180–250g. Animals were acclimatized
to the experimental conditions in metabolic cages and
kept under standard environmental conditions (22 ± 3◦C;
12/12h light/dark cycle). Rats were allowed to feed on
chow (Labina Purina—Brazil, CO) and water ad libitum.
T h ea n i m a l sw e r ea d a p t e dt om e t a b o l i cc a g e s3d a y sp r i o r
to the experiment. For acute toxicity test, adult male
Swiss mice (30–35g body weight) were used and kept
under the same environmental conditions. All experiments
reported herein are in accordance with the Animal Care
and Use Committee at the Federal University of Per-
nambuco and guidelines for Care and Use of Laboratory
Animals.
2.5. Acute Oral Toxicity Test. Acute toxicity (LD50)w a s
estimated in mice using the dose limit of the up and down
procedure, according to the Organization for Economic
Cooperation and Development (OECD) test guideline 425.
Acute Oral Toxicity was estimated using a computer-based
Statistical Program—AOT425statPgm, version: 1.0, at a dose
limit of 5g/kg body weight/oral route and default of Sigma at
0.5 [16, 17].
2.6. Induction of Diabetes. Diabetes was induced in
overnight-fasted rats by a single intraperitoneal injection
of 150mg/kgb.w. of freshly-prepared alloxan monohydrate
(Sigma, St. Louis, MO, USA), dissolved in sterile saline
solution (0.9%NaCl). After alloxan administration, all
animals were relocated to their cages and given free access to
food and water. The diabetic state was assessed by measuring
the serum blood glucose levels 3 days afterwards. Rats with
fasting glucose of above 250mg/dL were considered diabetic.
2.7. Evaluation of the Subchronic Oral Treatment. The rats
were divided into seven groups (3 normal and 4 diabetic),
consisting of 6 animals each. For normal rats, the control
group was assigned to normal control (NC), which received
the vehicle, and two groups of normal treated rats that
received HEPA by gavage daily at doses of 125mg/kg
(NT125) or 250mg/kg (NT250). The groups of diabetic rats
were as follows. Diabetic untreated group, which received
the vehicle and was assigned as the diabetic control group
(DC), and two groups of diabetic-treated rats that received
HEPA by gavage daily at doses of 125mg/kg (DT125) or
250mg/kg (DT250). Additionally, another group of diabetic
rats was treated with insulin (DTI) and adopted as a positive
treatment group. This group was treated twice a day (8a.m.
and 5p.m.) by subcutaneous injection with 3 units of NPH
insulin (Humolin NU-100, Eli Lilly, Brazil). All treatments
were carried out for 16 days.
Oral glucose tolerance test was performed using a
method previously described by Sezik and coworkers [18].
The animals were randomly divided into six groups (n = 6
animal/group), as follows: DC, DT125, DT250, NC, NT125,
and NT250. After overnight fasting, the 0-min blood sample
was taken from the rats by orbital sinus puncture for deter-
mination of fasting blood glucose. Glucose (2g/kgb.w.) was
orally administered at 30min after an oral administration of
the plant extract or vehicle (for control). Blood glucose was
measured by enzymatic methods, just before and 1/2h, 1h,
2h, 4h after the oral administration of the HEPA.
2.9.BiochemicalandPhysiologicalAnalysis. Underlightether
anesthesia, blood samples were withdrawn from the rat-
orbitalsinuswithacapillarytubeforbiochemicalparameters
determination. Serum glucose, cholesterol, triglycerides,
HDL-cholesterol, urinary glucose, and urea were measured
by enzymatic methods (Labtest Diagnostica, Brazil/SA).
Hepatic glycogen was extracted with 30%KOH and precip-
itated with alcohol [19] and quantiﬁed by the colorimetric
anthrone method [20]. In addition, body weight, food
and liquid intake (water), and urine volume were also
evaluated. All the parameters were measured before andEvidence-Based Complementary and Alternative Medicine 3
Table 1: Phytochemical result of the aerial parts hydroalcoholic
extract of Parkinsonia aculeata.
Tests Result
Alkaloids
(i) Drangendoﬀ’s test −
(ii) Wagner’s test −
(iii) Mayer’s test −
Saponins
(i) Emulsion test −
(ii) Frothing test −
Tanins
( i )B r o m i n ew a t e rt e s t + +
(ii) Ferric chloride test ++
Flavonoids
(i) Sodium chloride test +++
(ii) Magnesium ribbon test +++
Steroids
(i) Lieberman-Burchard test ++
(−) Not detected; (+) present in low concentration; (++) present in
moderate concentration; (+++) present in high concentration.
on the 16th day of treatment. After the last measurement,
the rats were sacriﬁced by decapitation. The epididymal
adipose tissue (EAT) lying over psoas, the soleus and extensor
digitorum longus (EDL) skeletal muscles, kidney, and liver
were removed and weighed.
2.10. Statistical Analysis. The results of experiments per-
formed in at least six independent experiments in duplicate,
are displayed as mean ± S.E.M. Multiple comparisons were
tested by one-way ANOVA, followed by Tukey’s post hoc test,
with the signiﬁcance level set at P<. 05 using SPSS software
(SPSS for Windows, version 16.0, Chicago, IL).
3. Results
3.1. Phytochemical Analysis. The synopsis of the simple
qualitative and quantitative analysis carried out on the plant
extract is shown in Table 1.
3.2. Acute Oral Toxicity Test. Oral administration of a dose
limit of 5g/kg of the HEPA did not result in any lethality
or observable behavioral changes such as writhing, gasping,
palpitation, and decreased respiratory rate, in the treated
mice. The oral acute toxicity of P. aculeata was, therefore,
considered as unclassiﬁed, since the LD50 estimate from
the AOT425Pgm program was greater than 5g/kg of body
weight/oral route.
3.3. Impact of HEPA on Fasting Serum Glucose and Urinary
Glucose Levels. Daily treatment for 16 days with HEPA
(125 and 250mg/kg; p.o.), in alloxan-induced diabetic rats,
signiﬁcantly reduced serum glucose levels (Figure 1(a))i n
DT125 (51%), DT250 (36%), and DTI (74%) groups, when
compared to the DC group. Figure 1(b) shows that the
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Figure 1: Fasting serum glucose (a) and urinary glucose (b) levels
in diabetic rats after subchronic treatment with HEPA. DC: diabetic
control (vehicle); DT125: diabetic-treated with HEPA (125mg/Kg);
DT250: diabetic treated with HEPA (250mg/Kg); DTI: diabetic
treated with insulin. All values expressed as mean ± S.E.M. (n = 6).
One-way ANOVA with Tukey’s post hoc test was applied.
∗P <. 05
versus DC group.
treatment with HEPA for the same period also signiﬁcantly
decreased urinary glucose levels in diabetic-treated groups.
Once again, the positive control (DTI) decreased urinary
glucose levels. On the other hand, comparison of normal
(nondiabetic) groups (NC, NT125 and NT250) during the
entire 16 days of treatment showed no overall signiﬁcant
diﬀerences among these groups, regarding serum glucose
and urinary glucose levels (data not shown).
3.4. HEPA Ameliorates Liver Glycogen Content in Diabetic
Rats. Figure 2 demonstrates that, as expected, the alloxan-
diabetic rats presented a signiﬁcant decrease in hepatic
glycogen content, when compared with nondiabetic rats.
However, a signiﬁcant increase was observed in hepatic4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Hepatic glycogen content from diabetic and normal rats
after subchronic treatment with HEPA. NC: nondiabetic control
(vehicle); NT125: nondiabetic treated with HEPA (125mg/Kg);
NT250: nondiabetic treated with HEPA (250mg/Kg); DC: diabetic
control (vehicle); DT125: diabetic treated with HEPA (125mg/Kg);
DT250: diabetic treated with HEPA (250mg/Kg); DTI: diabetic
treated with insulin. All values represent mean ± S.E.M. (n = 6).
One-way ANOVA with Tukey’s post hoc test. aP <. 001 versus NC;
∗P <. 01 versus DC.
glycogen levels in diabetic rats after the subchronic HEPA
treatment with the concentrations of 125mg/kg (4.3-fold)
and 250mg/kg (10.8-fold), which showed similar eﬀects
when compared with the usual drug of treatment, insulin
(9.8-fold). In addition, we observed that this parameter was
increased with no statistical signiﬁcance (P>. 05) in normal
rats treated with HEPA.
3.5. Serum Triglycerides, Total Cholesterol and HDL-Cho-
lesterol Levels on HEPA Administration. The eﬀect of oral
administration of HEPA on serum triglycerides, total choles-
terol, and HDL-cholesterol levels are displayed in Table 2.
In comparison with the control values (DC), HEPA at the
dose of 250mg/kgb.w. (DT250) exhibited a reduction in
serum triglyceride levels (74%) that was more pronounced
than that observed with 125mg/kg b.w. (DT125) (69%)
and that produced by insulin treatment (48%). Moreover,
the normal treated groups (NT125 and NT250), in com-
parison with the NC group, showed signiﬁcant reductions
in serum triglyceride levels of 19% and 31%, respectively.
Total cholesterol and HDL-cholesterol serum levels did
not suﬀer any signiﬁcant alteration in any of the groups
(normalanddiabeticrats)subjectedtothesubchronicHEPA
treatment.
3.6. HEPA Reduces Urinary Urea Levels in Diabetic Rats.
The subchronic treatment with HEPA in the DT125 and
DT250 groups resulted in a signiﬁcant decrease in urinary
urea levels (g/24h) (Figure 3). The reductions observed
in the DT125 (58%) and DT250 (66%) groups were
similar to that obtained in the DTI group (65%). In the
normal treated groups, the urinary urea concentration was
unaﬀected.
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Figure 3: Urinary urea level from animals after 16 days of treatment
withHEPA.NC: nondiabetic control (vehicle); NT125: nondiabetic
treated with HEPA (125mg/Kg); NT250: nondiabetic treated with
HEPA (250mg/Kg); DC: diabetic control (vehicle); DT125: diabetic
treated with HEPA (125mg/Kg); DT250: diabetic treated with
HEPA (250mg/Kg); DTI: diabetic treated with insulin. The values
represent the mean ± S.E.M. (n = 6). One-way ANOVA with
Tukey’s post hoc test.
∗P <. 05 versus DC.
3.7. HEPA Improves Some Physiological Variables in Diabetic
Rats. The eﬀects of HEPA on physiological variables (body
weight, liquid and food intake, and urinary volume) are
displayed in Table 3 for diabetic groups. A signiﬁcant
increase in body weight was observed in the DT250 and
DTI groups when compared with the DC group. Indeed, the
DT125,DT250,andDTIgroupsshowedsigniﬁcantdecreases
inliquidintakeandurinaryvolume.Nochangewasobserved
in food intake in the diabetic groups. Additionally, HEPA
treatment did not modify the physiological variables cited in
nondiabetic rats (data not shown).
3.8. Eﬀect of HEPA on Liver, Kidney, EAT, EDL, and Soleus
Weight. As shown in Table 3, the treatment with HEPA
produced an improvement in kidneys, EAT, and skeletal
muscles (soleus a n dE D L )w e i g h ti nd i a b e t i c - t r e a t e dr a t s ,
when compared to DC. Furthermore, the liver weight was
improved only in the DT250 group, compared to DC.
Additionally, it may be observed that HEPA treatment has
no apparent eﬀect on normal rats (data not shown).
3.9. Oral Glucose Tolerance Test (OGTT). In diabetic rats,
the administration of HEPA (125 and 250mg/kgb.w.) orally
at 30min prior to glucose load resulted in an improvement
in glucose tolerance (Figure 4(b)). As shown, in all diabetic
and normal groups the serum glucose concentration peak
was observed after 1h. DT125 and DT250 treated rats
demonstrated improvements in glucose tolerance of 21%
and 20%, 28% and 20%, 39% and 34% at 1, 2, and 4h,
respectively, in comparison with the DC group. Conversely
in normal rats, only the NT250-treated group displayed a
slightly improved glucose tolerance at 2h, when compared
with normal control rats (NC) (Figure 4(a)).Evidence-Based Complementary and Alternative Medicine 5
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Figure 4: Oral glucose tolerance test (OGTT) in normal (a) and
diabetic (b) rats treated with HEPA. NC: nondiabetic control
(vehicle); NT125: nondiabetic treated with HEPA (125mg/Kg);
NT250: nondiabetic treated with HEPA (250mg/Kg); DC: diabetic
control (vehicle); DT125: diabetic treated with HEPA (125mg/Kg);
DT250: diabetic treated with HEPA (250mg/Kg). Each value is
expressed as the mean ± S.E.M. (n = 6 ) .F o rs t a t i s t i c a la n a l y s i sw a s
employing one-way ANOVA with Tukey’s post hoc test.
∗P <. 05
versus respective control group (NC or DC). Arrows indicate the
time of administration of extract or glucose.
4. Discussion
The present study investigated the antidiabetic eﬀects of the
hydroethanolic extract of P. aculeata in a model of alloxan-
induced diabetic rats as well as in normal rats. Alloxan
causesdiabetesthroughitsabilitytogeneratereactiveoxygen
species (ROS), which leads to a massive increase in cytosolic
calcium concentration and, consequently, a rapid destruc-
tion in the insulin-producing beta cells of the pancreas
[21, 22]. In the experimental model adopted in this work,
the animals submitted to alloxan injection presented clear
symptoms of severe diabetes, such as hyperglycemia, glucose
intolerance,muscularproteolysis,andadiposetissuelipolysis
leading to body weight loss, glycosuria, osmotic polyuria,
andother consequences.As expected, the improvement in all
assessed parameters produced by insulin treatment validates
our model.
Resultsfoundinthisstudyindicatethatthehydroethano-
lic extract from P. aculeata (HEPA, 125 and 250mg/kg),
administered orally for 16 days, is able to produce signiﬁcant
beneﬁcial eﬀects on carbohydrate metabolism in diabetic
rats, by reducing both serum and urinary glucose in treated
animals (Figures 1(a) and 1(b)). In addition, HEPA had no
eﬀect on carbohydrate metabolism in normal rats (data not
shown).
Liver glycogen is the primary storable form of glucose
and its levels are a direct reﬂection of insulin signaling [23].
Consequently,indiabetesmellitus,amarkeddecreaseinliver
glycogen levels is observed [24, 25]. Accordingly, our data
also showed signiﬁcant decrease in liver glycogen content in
diabetic rats; however, these animals presented an increase
in liver glycogen content after the treatment with HEPA
(Figure 2). This eﬀect could be attributed to stimulation
of glycogenesis and/or inhibition of glycogenolysis, possibly
linked to improvement on insulin signaling. This eﬀect
represents a signiﬁcant contribution to glycemic control.
As reported in this paper, improvements in other related
diabetic parameters, such as decreased osmotic diureses and
a reduction in water intake (Table 3)w e r ep r e d i c t a b l ea sa n
outcome of decreased glycemia. In accordance to our results,
other species of the Caesalpineaceae family, popularly used
as antidiabetics, have also been showed similar eﬀects on
carbohydrate metabolism [26–29].
In diabetes, there is an increase in protein catabolism,
mainly in skeletal muscles, with the ﬂow of amino acids
into the liver, providing substrates to gluconeogenesis [30].
In this way, changes in the proteolytic pathways promoted
by insulin deﬁciency lead to a marked muscular proteolysis,
responsible for muscular mass decrease [31]. Our reports
have shown that HEPA treatment in diabetic rats is able to
reduce the levels of urinary urea (Figure 3)a sw e l la sc a u s e
an improvement in the weight of skeletal muscles (soleus and
EDL) (Table 3). These ﬁndings might indicate that HEPA
exerts its eﬀect by the inhibition of gluconeogenesis. In
addition, although the diabetic control group presented a
body weight reduction, weight loss was lower in the diabetic-
treated groups. These beneﬁcial eﬀects could be related to
the ability to repair the protein breakdown and enhance the
glycemic control produced by the HEPA treatment.6 Evidence-Based Complementary and Alternative Medicine
Table 2: Serum total cholesterol, HDL-cholesterol, and triglycerides levels in normal and diabetic rats after subchronic treatment with
HEPA.
Groups Lipids concentration (mg/dL)
Total Cholesterol HDL-cholesterol Triglycerides
NC 77.34 ± 2.45 36.3 ± 1.5 103.27 ± 5.50
NT125 81.72 ± 2.47 40.6 ± 1.2 83.68 ± 3.93#
NT250 84.45 ± 5.83 41.2 ± 1.3 71.21 ± 4.18#
DC 85.83 ± 7.72 32.4 ± 2.2 253.92 ± 18.77
DT125 73.26 ± 9.74 33.9 ± 4.1 78.38 ± 10.52∗a
DT250 79.45 ± 3.92 37.7 ± 2.1 65.34 ± 8.68∗a
DTI 83.81 ± 3.43 41.2 ±1.8
∗ 132.15 ± 16.29∗a
Data represent the end of treatment (Day 16). NC: nondiabetic control (vehicle); NT125: nondiabetic treated with HEPA (125mg/Kg); NT250: nondiabetic
treated with HEPA (250mg/Kg); DC: diabetic control (vehicle); DT125: diabetic treated with HEPA (125mg/Kg); DT250: diabetic treated with HEPA
(250mg/Kg); DTI: diabetic treated with insulin. The values represent the mean ± S.E.M. (n = 6). One-way ANOVA with Tukey’s post hoc test. ∗P <. 05
versus DC group; #P <. 05 versus NC group; aP <. 05 versus DTI group.
Table 3: Eﬀects of subchronic treatment with HEPA on body weight, physiological variables, and weights (tissues (g) per 100g of body
weight) of liver, kidneys, epididymal adipose tissue (EAT), soleus and extensor digitorium longus (EDL) in alloxan-diabetic rats.
Metabolic Parameters NC DC DT125 DT250 DTI
Body Weight (g) 224.8 ± 6.4 147.8 ± 6.3 156.9 ± 10.2 172.7 ± 5.3∗ 205.5 ± 4.5∗
(+10.8%) (−9.5%) (−7.3%) (+8.2%) (+22.5%)
Liquid Intake (mL/24h) 28.3 ± 1.6 193.8 ± 7.5 140.1 ± 8.3∗ 128.6 ± 6.2∗ 90.3 ± 5.9∗
Food Intake (g/24h) 18.2 ± 1.8 35.6 ± 0.8 32.8 ± 1.2 30.1 ± 1.8 28.5 ± 1.2
Urinary Volume (mL/24h) 6.7 ± 1.1 136.3 ± 1.8 78.5 ± 4.1∗ 93.1 ± 3.5∗ 60.3 ± 4.7∗
Liver 4.85 ± 0.25 6.04 ± 0.20 5.37 ± 0.35 5.07 ± 0.17∗ 5.29 ± 0.21∗
Kidneys 0.44 ± 0.02 0.76 ± 0.02 0.49 ± 0.03a 0.47 ± 0.03a 0.46 ± 0.01a
EAT 0.87 ± 0.20 0.14 ± 0.01 0.19 ± 0.01∗ 0.95 ± 0.08∗ 0.79 ± 0.06∗
Soleus 0.07 ± 0.00 0.05 ± 0.00 0.06 ± 0.00# 0.07 ± 0.00# 0.06 ± 0.00#
EDL 0.06 ± 0.00 0.04 ± 0.00 0.05 ± 0.00∗ 0.06 ± 0.00∗ 0.05 ± 0.00∗
Data represent the end of treatment (Day 16). NC: nondiabetic control (vehicle); DC: diabetic control (vehicle); DT125: diabetic treated with HEPA
(125mg/Kg); DT250: diabetic treated with HEPA (250mg/Kg); DTI: diabetic treated with insulin. Values given are the mean ± S.E.M. (n = 6). One-way
ANOVA with Tukey’s post hoc test. ∗P <. 05; #P <. 01; aP <. 0001 versus DC. Percentage changes (ﬁgures in parenthesis) in body weight of all groups were
in comparison with yours initial (Day 0—opening of treatment).
Dysregulation of the lipid proﬁle is one of the most
common complications in diabetes and found in 40% of
diabetic cases [32]. Alloxan-induced diabetic rats showed an
important lipolytic activity, due to the insulinopenic state
that contributes to this alteration in the lipid proﬁle [33].
As shown in this work, the HEPA treatment did not present
any improvement in cholesterol and HDL—cholesterol
levels in diabetic- as well as normal-treated rats (Table 2);
these results diﬀer from those of our previous study that
employed the aqueous extract fraction [13]. Conversely,
HEPA treatment presented a relevant hypotriglyceridemic
eﬀect in diabetic rats and, surprisingly, this eﬀect was also
observed in normal rats (Table 2). These consequences of
HEPA treatment on the lipid proﬁle support a favorable
eﬀect on EAT weight of diabetic rats and suggest that the
mobilization of fatty acids from the peripheral fat depots
could be reduced. Recently, Sharma and co-workers [34]
demonstrated that P. aculeata seeds contain a high amount
of polyunsaturated fatty acids (PUFA). Several studies have
demonstrated that the intake of PUFA is associated with a
decrease in risk factors, such as triglycerides levels, in cardio-
vascular disease [35, 36]. Thus, these new data, reported for
P. aculeata is in line with the observed hypotriglyceridemic
eﬀect.
In this study, we also observed eﬀects of the treatment
with HEPA on the liver and kidney weights of diabetic-
treated rats (Table 3). Only the DT250-treated group showed
a signiﬁcant reduction in liver weight. The literature regard-
ing the eﬀect of diabetes on liver weight is contradictory,
as some studies have shown an increase in hepatic weight
[37], while others report no change [38]. With regard to
kidney weight, the treatment with HEPA caused a signiﬁcant
reduction. Diabetic animals tend to show renal hypertrophy
caused by an increased formation of advanced glycation end
products (AGE) and accumulation of glycogen granules in
distal tubules [39, 40].
In our previous study, it was reported that the aqueous
extract fraction of P. aculeata has antidiabetic properties
[13]. The current study shows that the hydroethanolic
extract of P. aculeata also has antidiabetic eﬀects, but
shows less potent eﬀects than the aqueous extract fraction.
The antidiabetic plant extracts may involve one or more
compounds to produce its eﬀects, suggesting that the natural
constituents could act separately or synergistically [7]. OurEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Schematic representation of the proposed eﬀects of the HEPA treatment in alloxan-induced diabetic rats. The group of diabetic rats
which were treated with the HEPA showed a signiﬁcant reduction in serum and urinary glucose, urinary urea, and triglyceride levels. Also,
an improvement in hepatic glycogen was observed as well as a decrease in liquid intake and urinary volume, and an enhancement in the
weightofskeletalmuscles,kidneys,liver,andadiposetissue.Indeed,oralglucosetolerancewashigherindiabeticanimalstreatedwithHEPA.
Together, all observed changes in some of the measured parameters, suggests a reduction on the gluconeogenesis process.
preliminary phytochemical screening of HEPA showed that
it contains tannins, steroids, and a high concentration of
ﬂavonoids. Additionally, previous phytochemical studies of
the P. aculeata leaves extract have shown the presence of
orientin, isoorientin, vitexin, and isovitexin (all glycosylated
ﬂavonoids) [41–43], which have beneﬁcial eﬀects in dia-
betes, ameliorating glucose tolerance, lipid proﬁle, glycogen
biosynthesis, glucose uptake, and insulin signaling [44–46].
In accordance with such observations, Sezik et al. [18]
suggested that the potent antidiabetic activity of isoorientin
is associated with its speciﬁc interaction with pancreatic β-
cells after systemic absorption and subsequent reversion of
the oxidative injury promoted by alloxan. In this context,
it is probable that the glycosylated ﬂavonoids found in the
P. aculeata extract produce its antidiabetic properties. These
compounds have a hydrosoluble carbohydrate radical that is
better extracted by more polar solvents, possibly explaining
the stronger antidiabetic eﬀects presented by treatment with
the aqueous extract fraction of P. aculeata.
One goal of therapy for diabetic patients is the main-
tenance of normal blood glucose levels, including control
of postprandial increases in blood glucose [47]. The glu-
cose load was well tolerated in the extract-treated groups.
Moreover, only the NT250 normal treated group presented
a discrete improvement in glucose tolerance (Figure 4(a)).
However, this eﬀect was not sustained, giving slightly
reduced values at the second hour after administration.
On the other hand, diabetic animals treated with HEPA
showed a signiﬁcant reduction at the ﬁrst hour of treatment,
and this eﬀect remains during all experiment (Figure 4(b)).
Some hypotheses may be raised to explain this amelioration
observed in the oral glucose tolerance test, including low-
ered intestinal glucose absorption and improvement in the
delayed insulin response. Accordingly, other workers have
utilized the same experimental design to demonstrate the
antidiabetic and glucose tolerance eﬀe c t so fp l a n te x t r a c t si n
experimentally induced diabetic rats [48–50].
Diﬀerent mechanisms of action of herbal extracts have
been reported to explain improvements in glycemic levels.
Some plants present actions similar to the well-known
sulfonylurea, which produces hypoglycemia in nondiabetic
animals [51]. Some other plants act similarly to biguanides,
an antihyperglycemic compound that act inhibiting the
gluconeogenesis and do not aﬀect blood glucose levels in
normoglycemicanimals[52].SinceP. aculeata didnotreduce
glycemia in normal rats, is possible that it acts in a similar
way to biguanides. However, the capacity of P. aculeata to
regenerate pancreatic β-cells should not be excluded as a
mechanism of action.
5. Conclusion
Based on this study, we conclude that the aerial parts
of P. aculeata represent a good candidate for alternative
and/or complementary medicine in the management of
diabetes mellitus, since the plant extract treatment exhibited
a high degree of toxicological safety and several beneﬁcial
eﬀects on diabetic animals (see Figure 5). Additionally, the8 Evidence-Based Complementary and Alternative Medicine
hypotriglyceridemic eﬀectofHEPA,observedinnormalrats,
should be highlighted. As observed in our previous studies
[13], the hydroethanolic extract of P. aculeata also did not
show a dose-dependent eﬀect on the majority of parameters
studied. Finally, results also indicate that P. aculeata contains
polar antidiabetic components.
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